Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
about
An update on antibody-based immunotherapies for Clostridium difficile infectionBiopharmaceuticals from microorganisms: from production to purificationImmunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and ProteinsEngineering potent long-acting variants of the Wnt inhibitor DKK2Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Elimination of N-glycosylation by site mutation further prolongs the half-life of IFN-α/Fc fusion proteins expressed in Pichia pastoris.Modulating immunogenicity of factor IX by fusion to an immunoglobulin Fc domain: a study using a hemophilia B mouse model.Half-life extended biotherapeutics.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Half-Life Extension of Biopharmaceuticals using Chemical Methods: Alternatives to PEGylation.Organophosphate-Hydrolyzing Enzymes as First-Line of Defence Against Nerve Agent-Poisoning: Perspectives and the Road Ahead.Recent advances in (therapeutic protein) drug development.Pharmacological Modulation of Radiation Damage. Does It Exist a Chance for Other Substances than Hematopoietic Growth Factors and Cytokines?Current progress in innovative engineered antibodies.Comparative N-Glycosylation Analysis of the Fc Portions of a Chimeric Human Coagulation Factor VIII and Immunoglobulin G1Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1.LAPS Insulin115: A novel ultra-long-acting basal insulin with a unique action profile.Novel approaches to hemophilia therapy: successes and challenges.Half-life extension using serum albumin-binding DARPin® domains.Synthesis of a Bifunctional Peptide Inhibitor-IgG1 Fc Fusion That Suppresses Experimental Autoimmune Encephalomyelitis.Production of Nα-acetyl Tα1-HSA through in vitro acetylation by RimJ.Evolution of the magic bullet: Single chain antibody fragments for the targeted delivery of immunomodulatory proteins.High yield process for the production of active human α-galactosidase a in CHO-K1 cells through lentivirus transgenesis.Recombinant Proteins and Monoclonal Antibodies.Progress in biopharmaceutical development.Metal-bound claMP Tag inhibits proteolytic cleavage.Construction, Purification, and Characterization of a Homodimeric Granulocyte Colony-Stimulating Factor.Aligning physics and physiology: Engineering antibodies for radionuclide delivery.Novel hemostatic biomolecules based on elastin-like polypeptides and the self-assembling peptide RADA-16.Recombinant immunotoxins with albumin-binding domains have long half-lives and high antitumor activity.Fc-fusion mimetics.Characterization of the hypersensitive response-like cell death phenomenon induced by targeting antiviral lectin griffithsin to the secretory pathway.Emerging therapies for hemophilia: controversies and unanswered questions.Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life
P2860
Q26740788-EFB8A1FF-37D0-4A73-AE38-CA0F69FF0D6BQ28066997-F9E8FDF7-2FB0-427D-AE66-A6B99165B05EQ28072319-5DF04920-3C87-4BDB-9849-0D2CF25DBC95Q33659386-A1ECAA7E-6E23-43C8-A68E-1FF234F78420Q36393594-389A6F00-7A35-44C1-B1E1-75561B59121BQ37481254-717BDE67-FCBF-47EA-9C52-D12CC8700AACQ38760836-84F9DE9E-27BF-4B6F-A1D9-317B971B50ABQ38770067-19CFD446-FF93-4854-8B03-BDB2DB200C37Q38929801-F551BF44-1617-4BEB-B491-DA18D0D471B8Q38989309-2B54FFEB-D31A-409F-99F3-9F2D1D4C12E3Q39004225-E140423F-C399-4AE8-9B01-18BE1CBDB826Q39148639-51A4C0CE-6A7F-4540-BD45-74CEFA455476Q39402305-3E358628-3A8A-4774-A5B5-F846B5CEC3E2Q40077818-094694B6-6F0C-456E-970D-808B32ED4565Q41512058-B6C0B15F-41B5-4EEF-8815-F16226B9F637Q41573532-36B521E8-D4D9-4F07-873E-11B74411F6A3Q42509647-2E858E65-9F6D-4A24-B736-714E805362C9Q45873013-FFE140DC-C57F-4DB4-BD54-D14121A26DE8Q46271471-540F29F1-E471-44F2-A049-BD68038DFFD8Q46299475-8277758A-BD3C-4A68-B5C4-415FC10E214AQ47120475-520C95BC-CC65-418A-B609-30C36C9A4766Q47277628-1BE33010-467C-47A2-A779-EC8558D5BBF1Q47288227-A9529C49-C447-40E7-8BFE-AEE9D162D253Q47602370-B54C9628-ED5C-41D6-B50D-6A4E84CF2446Q48253463-61025481-02C9-47AD-B4F7-CDE41958EF36Q50624935-C27774E8-64F4-4DE3-86C4-A3E77C2FD6AEQ50882900-D010575E-36AD-4C9C-B2D7-C85F75F2297EQ51740406-355ADC58-083A-44D2-9E73-AD872E0C7CF0Q52668901-15900300-944E-41A6-8A13-5302F9283225Q52723975-61CD1325-034D-4290-9A0B-D821849B7C47Q54197670-1ADA776C-264E-4525-8090-227B0CCB3352Q54261381-A29CBBEB-F753-4A31-9BC6-C65E56988F8BQ54958581-E039435F-775F-4BDB-9474-405880D03DB6Q58771453-AF0D1C82-73C7-4640-8326-818ADB992D1A
P2860
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@ast
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@en
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@nl
type
label
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@ast
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@en
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@nl
prefLabel
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@ast
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@en
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@nl
P2860
P3181
P1433
P1476
Fusion Proteins for Half-Life Extension of Biologics as a Strategy to Make Biobetters
@en
P2093
William R Strohl
P2860
P2888
P304
P3181
P356
10.1007/S40259-015-0133-6
P407
P577
2015-08-01T00:00:00Z
P5875
P6179
1026549245